Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

Summary

To learn if a process called neuromodulation can help to improve pain due to CIP

Detailed Description

Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds * Patients seen at Pain Management Center at MD Anderson Cancer Center * Patient ages greater or equal to 18 years but less than or equal to 85 years Exclusion Criteria: * Patients with cognitive dysfunction * Patient with recent history (\<6 months) of drug or alcohol abuse * Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection * Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy

Eligibility Criteria

Interventions